Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Double-blind, Randomized, Placebo-controlled Study of NasoVAX in the Prevention of Clinical Worsening in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)

NCT04442230 is registered in ClinicalTrials.gov with Altimmune, Inc. as lead sponsor.

NCT NCT04442230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04442230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Double-blind, Randomized, Placebo-controlled Study of NasoVAX in the Prevention of Clinical Worsening in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)
Lead sponsor
Altimmune, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
October 10, 2020
Completion date
February 15, 2021
Enrollment
48 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus infection